Variant report
Variant | nsv602844 |
---|---|
Chromosome Location | chr6:33935903-33942640 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:14)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
(count:14 , 50 per page) page:
1
No. | Distal block | Cell Line | Cell type | Cell Stage |
---|---|---|---|---|
1 | chr6:33935283..33936415-chr6:33994982..33996031,6 | MCF-7 | breast: | |
2 | chr6:33935012..33937459-chr6:33942472..33944353,2 | K562 | blood: | |
3 | chr6:33935558..33936417-chr6:34023156..34023663,2 | K562 | blood: | |
4 | chr6:33936123..33939292-chr6:33941917..33944139,3 | MCF-7 | breast: | |
5 | chr6:33935782..33936335-chr6:33955656..33956622,2 | MCF-7 | breast: | |
6 | chr6:33935012..33937286-chr6:33941317..33943972,2 | K562 | blood: | |
7 | chr6:33928944..33932796-chr6:33933214..33936694,5 | K562 | blood: | |
8 | chr6:33935012..33937459-chr6:33942472..33944353,2 | K562 | blood: | |
9 | chr6:33936123..33939292-chr6:33941917..33944139,3 | MCF-7 | breast: | |
10 | chr6:33819352..33820057-chr6:33935715..33936362,3 | MCF-7 | breast: | |
11 | chr6:33934133..33938274-chr6:33943444..33948778,6 | MCF-7 | breast: | |
12 | chr6:33935012..33937286-chr6:33941317..33943972,2 | K562 | blood: | |
13 | chr6:33935685..33937732-chr6:33955927..33958373,2 | MCF-7 | breast: | |
14 | chr6:33819661..33820304-chr6:33935521..33936307,2 | MCF-7 | breast: |
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs9469655 | chr6:33935903-33935904 | Weak transcription Bivalent Enhancer Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
2 | rs187197916 | chr6:33935919-33935920 | Weak transcription Bivalent Enhancer Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs540789050 | chr6:33935926-33935927 | Weak transcription Bivalent Enhancer Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs189742701 | chr6:33935952-33935953 | Weak transcription Bivalent Enhancer Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs529921197 | chr6:33935975-33935976 | Weak transcription Bivalent Enhancer Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs570765262 | chr6:33935986-33935987 | Weak transcription Bivalent Enhancer Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs548481148 | chr6:33936009-33936010 | Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
8 | rs556221135 | chr6:33936070-33936071 | Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
9 | rs35628510 | chr6:33936071-33936072 | Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
10 | rs73402454 | chr6:33936082-33936083 | Weak transcription Bivalent Enhancer | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
11 | rs111269582 | chr6:33936156-33936157 | Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
12 | rs139836222 | chr6:33936190-33936191 | Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
13 | rs374573359 | chr6:33936198-33936199 | Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
14 | rs550295528 | chr6:33936215-33936216 | Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
15 | rs571728651 | chr6:33936229-33936230 | Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
16 | rs141553256 | chr6:33936240-33936241 | Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
17 | rs547981706 | chr6:33936283-33936284 | Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
18 | rs182358077 | chr6:33936300-33936301 | Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
19 | rs536527792 | chr6:33936331-33936332 | Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
20 | rs79471497 | chr6:33936366-33936367 | Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
21 | rs185652232 | chr6:33936439-33936440 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
22 | rs374656416 | chr6:33936477-33936478 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
23 | rs575943288 | chr6:33936507-33936508 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
24 | rs190358805 | chr6:33936525-33936526 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
25 | rs183422064 | chr6:33936531-33936532 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
26 | rs9380394 | chr6:33936538-33936539 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
27 | rs540752315 | chr6:33936569-33936570 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
28 | rs559250811 | chr6:33936695-33936696 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
29 | rs188825219 | chr6:33936708-33936709 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
30 | rs568533771 | chr6:33936714-33936715 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
31 | rs372426228 | chr6:33936761-33936762 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
32 | rs563649177 | chr6:33936790-33936791 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
33 | rs564780253 | chr6:33936827-33936828 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
34 | rs550150768 | chr6:33936856-33936857 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
35 | rs565301730 | chr6:33936857-33936858 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
36 | rs532616358 | chr6:33936917-33936918 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
37 | rs7755524 | chr6:33936925-33936926 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
38 | rs370608323 | chr6:33936936-33936937 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
39 | rs566116919 | chr6:33936937-33936938 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
40 | rs542296386 | chr6:33936981-33936982 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
41 | rs60799232 | chr6:33937025-33937026 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
42 | rs530713368 | chr6:33937033-33937034 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
43 | rs530815574 | chr6:33937056-33937057 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
44 | rs191621755 | chr6:33937072-33937073 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
45 | rs577140519 | chr6:33937123-33937124 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
46 | rs75794266 | chr6:33937126-33937127 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
47 | rs572775644 | chr6:33937128-33937129 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
48 | rs12110641 | chr6:33937188-33937189 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
49 | rs570131701 | chr6:33937227-33937228 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
50 | rs549687834 | chr6:33937268-33937269 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Follicular lymphoma | 20505157 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Leukemia | 21518781 | CNVD |
Cancer | 21637783 | CNVD |
Facial dysmorphism | 22105932 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
Diffuse large b-cell lymphoma | 18287131 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Glioblastoma multiforme | 19960244 | CNVD |
Hepatocellular carcinoma | 22174799 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Acute myeloid leukemia | 16864856 | CNVD |
Breast cancer | 21264507 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Cancer | 16751803 | CNVD |
Bladder cancer | 19088036 | CNVD |
Wilms tumour | 21544195 | CNVD |
Uveal melanoma | 21693616 | CNVD |
Biliary cancer | 19435499 | CNVD |
Malaria | 21533027 | CNVD |
Retinoblastoma | 19183342 | CNVD |
Acute myeloid leukemia | 20729466 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Prostate cancer | 18632612 | CNVD |
Breast cancer | 21858162 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
Autism | 21448237 | CNVD |
Melanoma | 18172304 | CNVD |
Breast cancer | 20668451 | CNVD |
Cancer | 20668451 | CNVD |
Lung cancer | 20668451 | CNVD |
Ovarian cancer | 20668451 | CNVD |
Pancreas cancer | 20668451 | CNVD |
Prostate cancer | 20668451 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Hepatocellular carcinoma | 16750200 | CNVD |
Autism | 22495311 | CNVD |
Cancer | 16790693 | CNVD |
Cervical cancer | 21062161 | CNVD |
Esophageal adenocarcinoma | 18820669 | CNVD |
Systemic lupus erythematosus | 17503323 | CNVD |
Endometrioid adenocarcinoma | 16974079 | CNVD |
Urothelial carcinoma | 18382360 | CNVD |
Cancer | 21183584 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Oral squamous cell carcinoma | 17134496 | CNVD |
Gastric cancer | 17908304 | CNVD |
Metanephric adenoma | 20802469 | CNVD |
Splenic marginal zone lymphoma | 21957467 | CNVD |
Schizophrenia | 19571808 | CNVD |
Malignant peripheral nerve sheath tumor | 18522746 | CNVD |
Neuroblastoma | 16790693 | CNVD |
T-cell prolymphocytic leukemia | 17713554 | CNVD |
abnormal development | 18461090 | CNVD |
Breast cancer | 16397240 | CNVD |
Retinoblastoma | 22278416 | CNVD |
Non-syndromic sensorineural hearing loss | 15273396 | CNVD |
Systemic lupus erythematosus | 20877625 | CNVD |
Cleidocranial dysplasia | 18696259 | CNVD |
Holoprosencephaly | 21359414 | CNVD |
Liposarcoma | 21253554 | CNVD |
Uveal melanoma | 20484589 | CNVD |
Fibroblasts | 20926602 | CNVD |
Systemic lupus erythematosus | 19279649 | CNVD |
Retinoblastoma | 16790693 | CNVD |
Acute myocardial infarction | 18032375 | CNVD |
Renal cell carcinoma | 19150565 | CNVD |
Systemic lupus erythematosus | 19591781 | CNVD |
Attention deficit hyperactivity disorder | 19287146 | CNVD |
Autism | 19287146 | CNVD |
Erythema nodosum in leprosy | 19287146 | CNVD |
Henoch-schoenlein purpura | 19287146 | CNVD |
Liver cirrhosis | 19287146 | CNVD |
Systemic lupus erythematosus | 19287146 | CNVD |
Autoimmune disease | 19135723 | CNVD |
Congenital adrenal hyperplasia | 18478071 | CNVD |
Systemic lupus erythematosus | 19287147 | CNVD |
Osteosarcoma | 16790693 | CNVD |
Biliary cancer | 20360734 | CNVD |
Breast cancer | 20360734 | CNVD |
Coronary artery disease | 20360734 | CNVD |
Crohn''s disease | 20360734 | CNVD |
Hypertension | 20360734 | CNVD |
Rheumatoid arthritis | 20360734 | CNVD |
Type 1 diabetes | 20360734 | CNVD |
Type 2 diabetes | 20360734 | CNVD |
Cancer | 22183965 | CNVD |
Melanoma | 22183965 | CNVD |
Acute lymphoblastic leukemia | 22237106 | CNVD |
Lung cancer | 18438408 | CNVD |
Glioblastoma multiforme | 21138945 | CNVD |
Breast cancer | 21364760 | CNVD |
Urothelial carcinoma | 21177765 | CNVD |
Basal cell lymphoma | 19029149 | CNVD |
Diffuse large b-cell lymphoma | 19029149 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Liver carcinoma | 19366792 | CNVD |
Chronic lymphocytic leukemia | 22228453 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr6:33927000-33942400 | Weak transcription | iPS DF 19.11 Cell Line | embryonic stem cell |
2 | chr6:33934800-33943600 | Weak transcription | ES-UCSF4 Cell Line | embryonic stem cell |
3 | chr6:33935600-33936000 | Enhancers | Fetal Muscle Leg | muscle |
4 | chr6:33935600-33936400 | Bivalent Enhancer | NHDF-Ad | bronchial |
5 | chr6:33935800-33936200 | Bivalent Enhancer | Adipose Derived Mesenchymal Stem Cell Cultured Cells | ES cell derived |
6 | chr6:33935800-33936200 | Bivalent Enhancer | Foreskin Fibroblast Primary Cells skin01 | Skin |
7 | chr6:33941800-33942800 | Enhancers | HUES48 Cell Line | embryonic stem cell |
8 | chr6:33941800-33942800 | Enhancers | iPS-18 Cell Line | embryonic stem cell |
9 | chr6:33941800-33942800 | Bivalent/Poised TSS | Rectal Mucosa Donor 29 | rectum |
10 | chr6:33942000-33942200 | Enhancers | iPS-20b Cell Line | embryonic stem cell |
11 | chr6:33942000-33942400 | Active TSS | Rectal Mucosa Donor 31 | rectum |
12 | chr6:33942000-33942600 | Bivalent Enhancer | HUES64 Cell Line | embryonic stem cell |
13 | chr6:33942000-33942800 | Enhancers | H1 Cell Line | embryonic stem cell |
14 | chr6:33942400-33942600 | Flanking Bivalent TSS/Enh | iPS DF 6.9 Cell Line | embryonic stem cell |
15 | chr6:33942400-33942800 | Bivalent Enhancer | HUES6 Cell Line | embryonic stem cell |
16 | chr6:33942400-33942800 | Enhancers | iPS DF 19.11 Cell Line | embryonic stem cell |
17 | chr6:33942400-33942800 | Flanking Active TSS | Rectal Mucosa Donor 31 | rectum |